跳至主要内容
临床试验/CTRI/2025/12/098988
CTRI/2025/12/098988尚未招募2/3 期

Efficacy of shatapushpa taila matra basti with oral administration of yograja guggulu and kumaryasava in the management of polycystic ovarian syndrome A single arm clinical study

All India Institute of Ayurveda1 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2026年3月8日最近更新:

试验速览

阶段
2/3 期
状态
尚未招募
入组人数
35
试验地点
1
主要终点
Reduction in ovarian volume in USG pelvis findings

研究概览

简要总结

RESEARCH QUESTION- What is the effect of Shatapushpa Taila Matra Basti 60ml for 7 days for three consecutive cycles after menses with oral administration of Yograja Guggulu 500mg 2 BD and Kumaryasava 20ml BD for 90 days in the management of PCOS?

HYPOTHESIS- Administration of Shatapushpa Taila Matra Basti along with oral Yograja Guggulu and Kumaryasava is effective in improving clinical sign symptoms and hormonal profile in patients with Polycystic Ovarian Syndrome (PCOS).

NULL HYPOTHESIS- Administration of Shatapushpa Taila Matra Basti 60ml for 7 days for three consecutive cycles after menses with oral administration of Yograja Guggulu 500mg 2BD and Kumaryasava 20ml BD for 90days is not effective in improving clinical sign symtoms and hormonal profile in PCOS.

ALTERNATE HYPOTHESIS- Administration of Shatapushpa Taila Matra Basti 60ml for 7 days for three consecutive cycles after menses with oral administration of Yograj Guggulu 500mg 2BD and Kumaryasava 20ml BD for 90days is effective in improving clinical sign symtoms and hormonal profile in PCOS.

NEED OF STUDY- PCOS is a heterogeneous endocrine disorder that affects one in 15 women worldwide. It is the most frequent cause of hyperandrogenism & anovulation which have substantial psychological, social & economic consequences. Lifestyle changes & lack of awareness are considered to be the major factor leading to this phenomenon. In modern system of medicine oral contraceptives, ovulation induction agents, progestin, antiandrogens and surgical interventions remain standard therapies having a number of side effects like Depression, Weight gain, Hot flushes, Hepatotoxicity and Nephrotoxicity etc. If PCOS is not treated timely it may lead to cardiovascular disease, endometrial cancer and ovarian cancer. it may lead to infertility, Risk of miscarriages and a high risk of developing diabetes, high blood pressure and other health complications. Therefore there is increased demand to address the problem from view of Ayurvedic medicine which gives better relief, it becomes important in field of Ayurveda develop a safe, cost effective, conservative, non invasive treatment protocol for PCOS. In Ayurveda (PCOS) can be classified as Granthibhoot Artava Dushti due to Vatakaphaja dosha. To restore normal menstruation Vatakaphanashak chikitsa is equally important. The treatment should aim at the correction of obesity and clear the Aavarana by using Vata Kapha Shamaka drugs which certainly help in the proper ovulation and menstruation.

OBJECTIVES: Primary Objective: • To evaluate the efficacy of Shatpushpa Taila Matra Basti with oral administration of Yograja Guggulu and Kumaryasava in reduction of ovarian volume.

Secondary Objectives: • To observe changes(interval, duration, menstural blood flow, pain during mensturation) in menstrual cycle and improvement in hormonal profile. • To evaluate changes in the following • Acne • BMI • Hirsutism(Ferriman-Gallwey scale)

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 40.00 Year(s)(—)
性别
Female

入选标准

  • 1 Female patient aged 18 to 40 years married or unmarried diagnosed with PCOS by Rotterdam Criteria must meet at least 2 of 3 Anovulation oligo or amenorrhea Hyperandrogenism clinical or biochemical Polycystic ovaries on ultrasound A polycystic ovary is defined as an ovary containing 12 or more follicles or 25 or more follicles using new ultrasound technology measuring 2 to 9 mm in diameter or an ovary that has a volume of greater than 10 mL on ultrasonography 2 Patient must be willing to provide voluntary informed consent 3 NIH Criteria 1990 To include both of the following Oligo ovulation Hyperandrogenism 4 AE PCOS 2009 1 Hyperandrogenism hirsutism and or hyperandrogenemia 2 Ovarian dysfunction Oligo-anovulation and or polycystic ovaries 3 Exclusion of other androgen excess or related disorders.

排除标准

  • a Primary amenorrhea b Pregnancy c Pelvic systemic conditions causing oligo anovulation or other gynecological disorders endometriosis hydrosalpinx uterine fibroids d Endocrine disorders unrelated to PCOS thyroid disease hyperprolactinemia congenital adrenal hyperplasia pituitary adenomas e Organic reproductive tract lesions tuberculosis malignancy carcinoma f Chronic systemic disease hypertension diabetes liver or renal disease Cushing’s syndrome cardiovascular disease.

结局指标

主要结局

Reduction in ovarian volume in USG pelvis findings

时间窗: Reduction in ovarian volume in USG pelvis findings in 3 months

次要结局

  • Regulation of menstrual cycle hormonal profile decreases acne BMI hirsutism(Regulation of menstrual cycle in 3months)

研究者

申办方类型
Government medical college
责任方
Principal Investigator
主要研究者

Dr vinita dhakad

All india institute of ayurveda

研究点 (1)

Loading locations...

相似试验